Tellus Therapeutics

Tellus Therapeutics

Biotechnology, 517 Summit Trail Dr, Durham, North Carolina, 27278, United States, 1-10 Employees

tellustherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: 91********

Who is TELLUS THERAPEUTICS

Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus' lead candidate, TT-20, i...

Read More

map
  • 517 Summit Trail Dr, Durham, North Carolina, 27278, United States Headquarters: 517 Summit Trail Dr, Durham, North Carolina, 27278, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from TELLUS THERAPEUTICS

Tellus Therapeutics Org Chart and Mapping

Employees

Austin Schwartz

VP of Operations and Finance

Jaron Ballentine

VP Clinical Operations and Business Development

Eric Benner

Co-Founder, Chief Scientific Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Tellus Therapeutics

Answer: Tellus Therapeutics's headquarters are located at 517 Summit Trail Dr, Durham, North Carolina, 27278, United States

Answer: Tellus Therapeutics's phone number is 91********

Answer: Tellus Therapeutics's official website is https://tellustherapeutics.com

Answer: Tellus Therapeutics's revenue is $1 Million to $5 Million

Answer: Tellus Therapeutics's SIC: 7389

Answer: Tellus Therapeutics has 1-10 employees

Answer: Tellus Therapeutics is in Biotechnology

Answer: Tellus Therapeutics contact info: Phone number: 91******** Website: https://tellustherapeutics.com

Answer: Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus' lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal models of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access